Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
60
SNSE Quote, Financials, Valuation and Earnings
Last price:
$9.27
Seasonality move
:
-6.39%
Day range:
$8.50 - $9.60
52-week range:
$5.00 - $18.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.43x
Volume:
22.5K
Avg. volume:
89.7K
1-year change:
5.91%
Market cap:
$11.6M
Revenue:
--
EPS (TTM):
-$10.67
Analysts' Opinion
-
Consensus RatingSensei Biotherapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $32.50, Sensei Biotherapeutics, Inc. has an estimated upside of 280.02% from its current price of $9.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 100% downside risk from its current price of $9.53.
Fair Value
-
According to the consensus of 1 analyst, Sensei Biotherapeutics, Inc. has 280.02% upside to fair value with a price target of $32.50 per share.
SNSE vs. S&P 500
-
Over the past 5 trading days, Sensei Biotherapeutics, Inc. has overperformed the S&P 500 by 11.76% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sensei Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sensei Biotherapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Sensei Biotherapeutics, Inc. reported revenues of --.
Earnings Growth
-
Sensei Biotherapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Sensei Biotherapeutics, Inc. reported earnings per share of -$3.91.
Enterprise value:
-14.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$346K
Return On Assets:
-58.48%
Net Income Margin (TTM):
--
Return On Equity:
-68.55%
Return On Invested Capital:
-62.44%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$1.9M | -$862K | -$346K | -$135K | -$37K | |
| Operating Income | -$46.9M | -$32.4M | -$27.6M | -$7.8M | -$5.2M | |
| EBITDA | -$45M | -$31.5M | -$27.3M | -$7.7M | -$5.2M | |
| Diluted EPS | -$1.47 | -$1.18 | -$10.65 | -$0.28 | -$3.91 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $165.6M | $127.5M | $81.1M | $53.9M | $29.6M | |
| Total Assets | $167.7M | $138M | $89.6M | $59.8M | $31.8M | |
| Current Liabilities | $3.9M | $5.4M | $5.4M | $4.9M | $3.9M | |
| Total Liabilities | $4.6M | $12.1M | $10.4M | $7.6M | $4.5M | |
| Total Equity | $163.1M | $125.9M | $79.2M | $52.2M | $27.3M | |
| Total Debt | $567K | $7.5M | $5.8M | $3.5M | $937K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$37.6M | -$24.2M | -$24.3M | -$5.8M | -$5.9M | |
| Cash From Investing | $46.4M | $29.3M | $25.7M | $6.9M | $8.8M | |
| Cash From Financing | -$8.5M | -$3.4M | -$780K | -$180K | -$168K | |
| Free Cash Flow | -$38M | -$24.4M | -$24.3M | -$5.9M | -$5.9M | |
SNSE
Sector
Market Cap
$11.6M
$28.1M
Price % of 52-Week High
50.19%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
5.34%
-1.49%
1-Year Price Total Return
1.88%
-17.13%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.68
200-day SMA
Buy
Level
$8.41
Bollinger Bands (100)
Buy
Level
7.71 - 10.63
Chaikin Money Flow
Buy
Level
48.5K
20-day SMA
Buy
Level
$8.71
Relative Strength Index (RSI14)
Buy
Level
54.44
ADX Line
Buy
Level
17.07
Williams %R
Neutral
Level
-69.7074
50-day SMA
Sell
Level
$9.57
MACD (12, 26)
Buy
Level
2.02
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
50.4K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.3068)
Sell
CA Score
(Annual)
Level (-1.1965)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (6.9799)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.
Stock Forecast FAQ
In the current month, SNSE has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SNSE average analyst price target in the past 3 months is $32.50.
-
Where Will Sensei Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sensei Biotherapeutics, Inc. share price will rise to $32.50 per share over the next 12 months.
-
What Do Analysts Say About Sensei Biotherapeutics, Inc.?
Analysts are divided on their view about Sensei Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sensei Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is Sensei Biotherapeutics, Inc.'s Price Target?
The price target for Sensei Biotherapeutics, Inc. over the next 1-year time period is forecast to be $32.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SNSE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sensei Biotherapeutics, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of SNSE?
You can purchase shares of Sensei Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sensei Biotherapeutics, Inc. shares.
-
What Is The Sensei Biotherapeutics, Inc. Share Price Today?
Sensei Biotherapeutics, Inc. was last trading at $9.27 per share. This represents the most recent stock quote for Sensei Biotherapeutics, Inc.. Yesterday, Sensei Biotherapeutics, Inc. closed at $9.53 per share.
-
How To Buy Sensei Biotherapeutics, Inc. Stock Online?
In order to purchase Sensei Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SNSE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SNSE
Sector
P/E ratio
--
23.89x
PEG ratio
0.00x
-0.01x
P/B ratio
0.43x
1.81x
Price / LTM sales
--
1.59x
Growth Metrics
SNSE
Sector
Revenue growth
--
4.62%
Earnings growth
-1296.43%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$3.34
-$0.21
Profitability
SNSE
Sector
Profitability FY 2024
-$551K
$3.6M
Return on invested capital
-62.44%
-31.84%
Return on assets
-58.48%
-27.96%
Return on equity
-68.55%
-37.63%
Earnings Date
Last Earnings Date
Dec
25
Next Earnings Date
Dec
25
Estimated Next Earnings Date
Mar
26
Balance Sheet
SNSE
Sector
Total cash
$28.6M
$26.4M
Short term investments
$31.3M
$25.7M
Total assets
$46.2M
$76.9M
Long term debt
$2.6M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
Sell
32
SMX alert for Dec 24
SMX (Security Matters) Plc [SMX] is down 8.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
